C-P9VZADvantage Therapeutics
immunomodulation, Klotho mRNA, neurodegeneration
modulatingimmunotherapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-P9VZ
C-P9VZC-P9VZimmunomodulation, Klotho mRNA, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The purpose of this randomized, placebo-controlled phase 2b study is to prospectively evaluate AD04's potential as a disease-modifying drug in AD. By evaluating the safety, pharmacodynamics, and efficacy of AD04 in early AD patients, we aim to deliver a comprehensive and robust data set that furthers our understanding of the effects of AD04 in AD pathology.
%PDF-1.6 %���� 1631 0 obj > endobj 1649 0 obj >/Filter/FlateDecode/ID[ ]/Index[1631 32]/Info 1630 0 R/Length 94/Prev 1903268/Root 1632 0 R/Size 1663/Type/XRef/W[1 2 1]>>stream h�bbd``b����@�i+�`�b� f{+�Z"^��;@,�� V6��"��s !]$&*301���I#���������A endstream endobj startxref 0 %%EOF 1661 0 obj >stream h��Y{tTչ?g�̜s��g�`�d1���҂8��M� i2����(*!��4��Iy8�c8A�yA Dle� o� ^ �X�dE���+j�&^Z����>��#!e������������=���ށ �0x�3F�1:�D&�J o!�0X� �-^Q�q8��~� ҈�N^6�#�L��I�ǫ����H �J�&zY�I�jj �|�s���G�q� �o�\:ڌ�ƽ�j� �*r����� �A�s�%)#����4 }���T�$�J� ��{�I�] !s$)�[x~�\B��%� … 11-02T07:33:03-04:00 2023-11-02T07:33:05-04:00 Adobe Illustrator 27.7 (Windows) application/postscript Type Setting Adobe Illustrator Artwork xmp.did:0f444349-a091-b446-bc80-f04f136b3cb3 xmp.iid:0ee0b293-6ecf-c444-a090-15c2471e060f uuid:acc17e50-f0a8-475e-884f-10febb7a479c uuid:41fe1c49-859a-4fc3-8f6c-9fe20cebc521 uuid:acc17e50-f0a8-475e-884f-10febb7a479c uuid:acc17e50-f0a8-475e-884f-10febb7a479c saved xmp.iid:0f444349-a091-b446-bc80-f04f136b3cb3 2023-11-02T07:33:05-04:00 Ado … cb3 2023-11-02T07:33:05-04:00 Adobe Illustrator 27.7 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator TouchUp 7.0 1 False False 39.000000 12.9 … ) 2023-07-17T10:07:06-04:00 2023-07-17T10:07:07-04:00 2023-07-17T10:07:07-04:00 application/postscript firedmanllp_logo Kishore Kumar Rajasekaran 1 False False 229.411994 31.087299 Pixels Cyan Magenta Yellow Black Default Swatch Group 0 xmp.did:497c060d-68c9-a14b-a19f-1b1f3b706ee8 xmp.iid:497c060d-68c9-a14b-a19f-1b1f3b706ee8 xmp.did:55db05e3-3f17-8c46-9ba9-b9ade7f33777 proof:pdf xmp.iid:c7ea2b09-39a4-9842-a343-e463def96214 xmp.did:c7ea2b09-39a4-9842-a343-e463def96214 xmp.did: … 2019-01-09T20:14:46-05:00 Adobe Illustrator CC 22.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6497e89a-048c-584a-8b75-fc2544d64558 2019-08-13T21:42:09-04:00 Adobe Illustrator CC 22.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6c53
Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscripti … ls Lighthouse Pharmaceuticals Liminal BioSciences Lincotek Medical LineaRx Link Fund Solutions Link Immunotherapeutics LivaNova LIVMOR Lobe Sciences Lobesity Pharma Longitude Capital Lonza Lorem Vascular LOTTE LTL Pharma LTS Lohmann Therapie-Systeme Lucy Scientific Discovery Lumenis Luminera LuminUltra LumiraDx LumiThera Lumos Pharma Lyell Immunopharma MAB Discovery MabVax Therapeutics Macrogen Macrogenics MacuHealth MacuLogix Magstim Mainz Biomed Mandos MannKind Biopharmaceu … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions  Report 455 Pages December 2025 Global From €4331 EUR $4,799 USD £3,755 GBP Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Product, Type of Cell Therapy, Scale of Operation, Type of End User and Key Geographical Regions  Report 250 Pages December 2025 Global Fr … uticals and Biotechnology 2019-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
Mark Hyman joins ADvantage Therapeutics Advisory Board | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
%PDF-1.4 1 0 obj > endobj 3 0 obj > endobj 4 0 obj [/Pattern /DeviceRGB] endobj 10 0 obj > >> endobj 11 0 obj > >> endobj 5 0 obj > endobj 14 0 obj > /ExtGState > /Pattern > /Font > /XObject > >> endobj 15 0 obj [ 10 0 R 11 0 R ] endobj 12 0 obj > stream x��]ˮ��߯�u��#>��� �E�� �E�E`� ۈ�E~?�n�� �_I��y2} ���*�w��b=-�ge�}�k���}��>�����t���N��������������|���ͧ�Y����s� �?� 8��q����:}�������ǯ ��F��h�������{�+��_:�h�b�-f_����b�-���?���ǖf_��.�Z*8N �i`o����Pݤ^'���k5bƘƷp�x�߉�:�f���,xm�3r��~O�������E{u"{ �x���Oh U�[�(=�% !Xp � R�s4�Nn�}�����YrڂJ��iWf�~;i��w�S��-�J�U�oj�rb�ݛ�:�� ۀ3�
%PDF-1.7 %���� 1 0 obj >/Metadata 1270 0 R/ViewerPreferences 1271 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��W[o[7 ~7�����b�E�r$ ���eX��v� � � I38�g��� )�c'n��}�C��>R�H�w�\?�Mn����T���(��R �PT�����^̺��Ǒ��n�}c� (m����w;�u;�OQE�J �.N�τ::'g��0p��a4Hp�:�B�$�&γ P�0-}�ʋ%G0�J�z�v��R�Z1m�+i +�K��L� ��K ) JjŴQed�Q�G#S����Je, ���F�:p��ƥUp-c1 ��� R�Z1mF��a�G#S������d�{�Nf���� \��\U&A�U�.���� @/�wL�A��[��Qi�����.*G
Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscripti … ls Lighthouse Pharmaceuticals Liminal BioSciences Lincotek Medical LineaRx Link Fund Solutions Link Immunotherapeutics LivaNova LIVMOR Lobe Sciences Lobesity Pharma Longitude Capital Lonza Lorem Vascular LOTTE LTL Pharma LTS Lohmann Therapie-Systeme Lucy Scientific Discovery Lumenis Luminera LuminUltra LumiraDx LumiThera Lumos Pharma Lyell Immunopharma MAB Discovery MabVax Therapeutics Macrogen Macrogenics MacuHealth MacuLogix Magstim Mainz Biomed Mandos MannKind Biopharmaceu … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions  Report 455 Pages December 2025 Global From €4331 EUR $4,799 USD £3,755 GBP Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Product, Type of Cell Therapy, Scale of Operation, Type of End User and Key Geographical Regions  Report 250 Pages December 2025 Global Fr … uticals and Biotechnology 2019-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-patt
Vienna BioCenter | Life Science Excellence at the heart of Europe Toggle Navigation Apply Contact Research Back Research at Vienna BioCenter Research Entities Research Areas Research Areas Open Submenu Back Back to Research Areas Anthropogenic Evolution Biochemistry, Biophysics, Structure Cell and Chromosome Biology Cognitive and Behavioral Biology Computational Biology, Genomes and Evolution Disease Mechanisms, Immunology, Pathogens Gene Regulation, RNA, Epigenetics Microbiology and Environmental Systems Science Neurobiology Plant Sciences Stem Cells, Development, Regeneration Research Groups … NE OF EUROPE'S HOTSPOTS FOR LIFE SCIENCES. RESEARCH. COMPANIES. EDUCATION. Apply now! COVID-19 PANDEMIC AT VIENNA BIOCENTER WE JOINED FORCES EARLY ON. WE DEVELOPED NEW DETECTION METHODS. WE INVENTED PCR TESTING ON POPULATION LEVEL. Read more here! Previous Next Vienna BioCenter - Top Life Science Cluster Over the last 30 years, the Vienna BioCenter has established itself as a top biology research center in Europe, comprising seven research institutions ( GMI … applied research in every organism imaginable. The basis for the revolutionary application of the CRISPR-Cas9 system was laid at the Max Perutz Labs at Vienna BioCenter. Read more MECHANISMS OF CHROMOSOME SEGREGATION MECHANISMS OF CHROMOSOME SEGREGATION The precise orchestration of chromosome segregation during cell division is an essential mechanism for all life. Research at the Vienna BioCenter has contributed greatly to illuminating the sophisticated mechanisms underlying … Advanced Grants awarded to Vienna BioCenter Researchers 22 Jun'26 E-STEEM Fellowship for Émeline Laborie to study centrosome biophysics 17 Jun'26 Net zero – using a basket to control enzymatic activity 11 Jun'26 WWTF funds research into precision medicine with a twist 21 May'26 Seven FWF Grants awarded to Vienna BioCenter Researchers 04 May'26 Choesin: putting the brakes on the genome’s folding motor 30 Apr'26 Long Night of Research 2026 23 Apr& … earch 2026 23 Apr'26 Sasha Mendjan‘s cardioid research honored with Houska Prize 23 Apr'26 IMP Scientists hijack cell machinery to destroy cancer-driving proteins 25 Mar'26 Traffic control at the molecular scale 13 Mar'26 Rethinking stem cell culture 09 Mar'26 FWF Emerging Fields Grants awarded to Vienna BioCenter Researc
BioPharma Updates 2nd December 2024 | SciLeads Features 3 2 Researcher Profiles Organization Profiles Tradeshow Calendar Search Builder Purchasing Data CRM Integration Solutions 3 2 Sales Marketing Data Analytics CROs API AI Partner Program Pricing Events Resources 3 2 Blog Case Studies eBooks Webinars Newsletter Company 3 2 About Us Careers Testimonials Partners Press & News Contact Login Free Trial a M Features 3 2 Researcher Profiles Organization Profiles Tradeshow Calendar Search Builder Purchasing Data CRM Integration Solutions 3 2 Sales Marketing Data Analytics CROs API AI Partner Progra … molecular analysis tools. Eisbach Bio (Munich, Germany) received a $4.75M CPRIT grant to support the clinical advancement of Eisbach’s groundbreaking allosteric small molecule inhibitor, EIS-12656, which targets ALC1—a chromatin remodeling enzyme and helicase considered a critical vulnerability in a significant subset of challenging-to-treat human cancers. Biotangents (St Andrews, United Kingdom) raised $2.8M to launch its on-farm diagnostic device for faster, more accu … IPO) Replimune (MA, USA) announced proposed public offering pricing of $140M to fund the development of its oncolytic immunotherapies and for general corporate purposes. Registered Direct Offering (RDO) Eyenovia Inc . (NY, USA) announced registered direct offering pricing of $1.3M to advance the company’s next-generation Optejet device, support commercialization activities for Mydcombi and clobetasol propionate, and explore strategic alternatives. Closures and Layoffs MediGen … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Features Researcher Profiles Organization Profiles Tradeshow Calendar Search Builder Purchasing Data CRM Integration Solutions Sales Marketing Data Analytics CROs API AI Partner Program Pricing Events Resources Resources Blog Case Studies eBooks Webinars Newsletter Free Tools Event Finder Funding Search Publications Search Tradeshow Data Company About Us Careers Testimonials Partners Press
Neuroscience News: AbbVie, BMS, Draig, C2N, iQure, Tonix, Coya, Aerska, Alpha Cognition, ADvantage, IRLAB, Klotho, POP, Nxera | Grant Smillie posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject … ure, Tonix, Coya, Aerska, Alpha Cognition, ADvantage, IRLAB, Klotho, POP, Nxera Grant Smillie 8mo Report this post 🚨🧠 Neuroscience News – 7 day recap: 03/10 ––– 𝘪𝘯 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱 𝘸𝘪𝘵𝘩 World CNS Series 🥼 Clinical News AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s Bristol Myers Squibb were granted FDA Fast Track Designation for BMS-986446, an anti-micotubule binding region tau antibody currently in Ph2 targeting Alzhei … ADvantage Therapeutics Inc. were awarded a $2.5M Ph2 Small Business Innovation grant from the NIH supporting AD04 targeting Alzheimer’s IRLAB Therapeutics AB received $4M from the McQuade Centre for Strategic Research and Development to further advance IRL757 targeting Parkinson’s Klotho Neurosciences (Nasdaq: KLTO) signed a letter of intent to acquire select assets from Turn Biotechnologies who focus on iPSC’s and cellular reprogramming POP Biotechnologies were awarded a $2 … on iPSC’s and cellular reprogramming POP Biotechnologies were awarded a $2.46M grant from the NIH to develop active immunotherapies with multiple amyloid beta and phosphor tau targets simultaneously 🤝 Collaborations Nxera received $10M from AbbVie in a second milestone payment in their multi target collaboration 57 11 Comments Like Comment Share Copy LinkedIn Facebook X Grant Smillie 8mo Report this comment Ovid Therapeutics have just this minute announced a private placeme … Profile Follow More from this author 🧠 Neuroscience News – 7 day recap: 20/01 Grant Smillie 4mo 🧠 Neuroscience News – 7 day recap: 23/01 Grant Smillie 5mo 🧠 Neuroscience News – 7 day recap: 09/01 Grant Smillie 5mo Explore related topics Promising Therapeutics for Alzheimer's Disease Latest Developments in Neurological Disorder Research How Te
Advantage Therapeutics - A new Vantage on Alzheimer’s Disease About Us Our Science Pipeline Our Team News New Approaches for treating Alzheimer’s Disease ADvantage Therapeutics leverages novel mechanisms of action to address AD Mission: ADvantage Therapeutics is developing novel therapeutics to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently approved for Phase 2 clinical trials in Europe and possess an ILAP Passport designation from MHRA in the UK which may permit simultaneous clinical enrollment and early commercialization in the U.K after p … dly, the patients from the control group significantly benefited from the AD04™ application. Patients treated with AD04™ saw reduced hippocampal shrinkage—a region critical for memory and spatial orientation—and a corresponding slowdown in cognitive decline. In 2021, Frank Mattner, Walter Schmidt, Agustin Fernandez and Jeffrey Madden founded ADvantage Therapeutics Inc. to provide Alzheimer’s patients with a transformative, life-enhancing treatment. Summary of Phase 2: A … aging related diseases... ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- “This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH... Klothea Bio Collaborates with Healthy Longevity Clinic, a Top 40 Semifinalist in $101 million XPRIZE Healthspan Competition Advantage Therapeutics Inc. Announc … ein for Age-Related Therapeutics Klothea Bio Secures Funding from Longevitytech.fund as a lead investor to Pioneer BreakthroughTreatments for Metabolic Syndrome and several Aging-Associated Diseases MIAMI, Nov. 25, 2024... ADvantage Therapeutics Welcomes Dr. William Haseltine as Strategic Advisor to Drive Innovation AD04T™ – modifying Alzheimer’s disease by modulation of hippocampal lipid metabolism AAIC24_Poster_template v5 ADvantage Therapeutics Announces Break … Wells Fargo. More recently Mr. Buchsbaum helped manage the Holtzman Opportunity Fund, a shareholder activist hedge fund and private equity holdings for Jewelcor. He has a J.D. in Law from the University of Miami and a B.S. in business from the University of Richmond. × Olivier Jarry Chief Operating Officer “Alzheimer’s is one of the last fr
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K   ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ACT OF 1934   For the fiscal period ended December 31 , 2025   or   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from                 to               & … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth comp … S disease, unveiling novel roles for KL. These findings highlight the potential application of muscle-secreted KL in ALS regardless of its origin and suggest broader therapeutic implications.   3     We are working with UAB scientists to advance our programs focused on neurodegenerative and age-related disorders — Alzheimer’s and ALS — all based on the Klotho gene and the s-KL protein. In addition to our product pipeline ca … xicology package for KLTO-202 and the submission of an Investigational New Drug application (IND) to the FDA in 2025 for permission to start the first-in-human Phase I “Compassionate Use” study of KLTO-202 in late-stage ALS patients. Likewise, the pre-clinical development program for KLTO-101, similar to that of KLTO-202, will follow behind the development of KLTO-202 by six to nine months. We plan to find a corporate partner to help in the development o … 268), Europe, China, Hong Kong, and pending in Canada. Patent applications (PCT Application No. PCT/EP2023/059677) filed in the major markets covering the composition and use of s-KL gene therapies to treat neuromuscular diseases like ALS are scheduled for review by the examiners in these countries.   Also, our team will pursue new innovatio
AD-04 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 20 Jun 2026 AD-04 Last update 20 Jun 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Immune cell therapy Synonyms AD-04(Advantage Therapeutics), AD-04(AFFiRiS AG), AD-04-AFFiRiS + [2] Target APP Action inhibitors Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) Therapeutic Areas Nervous System Diseases Active Indication Alzheimer Disease Inactive Indication - O … equent interactions with FDA and, if relevant criteria are met, eligibility for Rolling Review and other expedited review mechanisms. "As clinicians, we see every day the consequences of having limited disease-modifying options for patients with early Alzheimer's disease, especially those whose biology suggests inflammation is actively driving their decline," said Sharon Cohen, M.D., FRCPC, Behavioral Neurologist and Medical Director of the Toronto Memory Program, and a MINDF … borations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our a … borations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our a
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K   ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ACT OF 1934   For the fiscal period ended December 31 , 2024   or   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from                 to               & … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth comp … S disease, unveiling novel roles for KL. These findings highlight the potential application of muscle-secreted KL in ALS regardless of its origin and suggest broader therapeutic implications.   5     We are working with UAB scientists to advance our programs focused on neurodegenerative and age-related disorders — Alzheimer’s and ALS — all based on the Klotho gene and the s-KL protein. In addition to our product pipeline ca … xicology package for KLTO-202 and the submission of an Investigational New Drug application (IND) to the FDA in 2025 for permission to start the first-in-human Phase I “Compassionate Use” study of KLTO-202 in late-stage ALS patients. Likewise, the pre-clinical development program for KLTO-101, similar to that of KLTO-202, will follow behind the development of KLTO-202 by six to nine months. We plan to find a corporate partner to help in the development o … 268), Europe, China, Hong Kong, and pending in Canada. Patent applications (PCT Application No. PCT/EP2023/059677) filed in the major markets covering the composition and use of s-KL gene therapies to treat neuromuscular diseases like ALS are scheduled for review by the examiners in these countries.   Also, our team will pursue new innovatio
Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics - LISAvienna - life science austria Springe zum Inhalt Newsletter Downloads EN DE Über uns Unsere Services Services im Überblick Information & Beratung Networking & Matching Expertise Marketing Förderungen Geld einwerben Förderangebote Einreichtermine Private Equity Life Sciences in Wien Wissenswertes Für Start-ups Biotech & Pharma im Fokus Medizinprodukte aus Wien Globale Marktführer Wirtschaftsstandort Leben und Arbeiten in Wien News Verans … er, Managing Partner, QuadraScope, Jim O'Neill, Co-founder, the Thiel Fellowship, Former HHS Official, Dr. Achim Schneeberger, Chief Medical Officer, ADvantage Therapeutics, Yuri Deigin, Co-Founder, YouthBio Therapeutics, Petr Sramek, CEO, healthylongevity.clinic, Managing Partner, Longevitytech.fund, Dr. Jean Hebert, Professor, Albert Einstein College of Medicine, Daniel Gropper, Dean, FAU College of Business, Dr. Siri Terjesen, Phil S
Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development F … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics November 25, 2024 | 5 min read Twitter LinkedIn Facebook Email Print Klothea Bio Secures Funding from Longevitytech.fund as a lead investor to Pioneer Bre … d conditions. The new subsidiary is backed by seed funding led by Longevitytech.fund (“LTF”), a prominent venture capital fund managed by Petr Sramek that invests in biotechnology startups focused on healthy lifespan extension globally. Klothea Bio, Inc . will build upon Advantage Therapeutics’ proprietary IP portfolio centered around Klotho, a protein renowned for its significant anti-aging properties, including neuroprotection, antioxidative effects, and tumor suppression. … itude for the investment and highlighted the strategic focus that Longevitytech.fund will bring to the company's anti-aging research. “We are thrilled to partner with Longevitytech.fund as our lead investor, advancing our mission to realize the transformative potential of Klotho protein therapies for aging-related diseases. This collaboration strengthens Klothea Bio’s laser focus on developing safe and effective treatments as we prepare for our upcoming clinical trial, bringi … y human lifespan is achievable." Petr Sramek, Managing Partner of Longevitytech.fund and Klothea Board Member , expressed enthusiasm for supporting Klothea Bio’s mission. "Longevitytech.fund is committed to advancing solutions that address the hallmarks of aging, and we see Klotho as a critical protein in a molecular pathway to enhance human heal
Executive Management Archives - Advantage Therapeutics About Us Our Science Pipeline Our Team News Position: Executive Management Carmela Abraham, Ph.D. Thomas Hoffmann, Ph.D. Olivier Jarry David Buchsbaum Jeffrey B. Madden Walter Schmidt, Ph.D. Achim Schneeberger, M.D. Search Search Recent Posts Klothea Bio Announces the Launch of a Phase 1b Clinical Trial of AKL003, an Alpha Klotho mRNA Therapeutic, for the Extension of Human Lifespan Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio ADvantage Therapeutics Awarded $2. … ty Programs at Klothea Bio ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic Klothea Bio Collaborates with Healthy Longevity Clinic, a Top 40 Semifinalist in $101 million XPRIZE Healthspan Competition Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics Recent Comments No comments to show. Archives February 2 … ction arising out of or relating to these Terms. You and ADvantage Therapeutics submit to the personal jurisdiction of such courts for those purposes. Any claim either party has against the other under these Terms must be brought within one (1) year after the cause of action arises. 10. General. The Terms constitute the entire agreement between you and us, superseding any prior or contemporaneous communications and proposals (whether oral, written, or electronic) between you … conduct, and reporting of research funded under all Public Health Service (PHS) grant awards is not biased by any conflicting financial interests of an Investigator. In addition, the policy serves to protect the safety of animals and human research participants, the reputation of the recipient institution and of the Investigator who participates in PHS-funded research. These requirements work together to preserve the public’s trust that the research supported by the PHS is co … ote objectivity in Public Health Service (PHS) funded research. The regulations apply to all PHS (e.g., National Institutes of Health [NIH]) funded grants, cooperative agreements, and research contracts, with the exception of Phase 1 Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) applications and/or awards.
ADvantage Therapeutics Developing Therapies to Treat Neurodegenerative Conditions with Focus on Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search ADvantage Therapeutics Developing Therapies to Treat Neurodegenerative Conditions with Focus on Alzheimer’s Disease March 15, 2023 | 6 min read Twitter LinkedIn Facebook Email Print ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”) today announces it is working on the development of its lead candidate, the AD0 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ADvantage Therapeutics, Inc. Welcomes Dr. William A. Haseltine as Strategic Advisor to Drive Innovation in Alzheimer's Disease Research and Anti-aging Therapies such as Klotho Protein Supplementation to Extend Healthy Human Lifespan - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Pres … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases ADvantage Therapeutics, Inc. Welcomes Dr. William A. Haseltine as Strategic Advisor to Drive Innovation in Alzheimer’s Disease Research and Anti-aging Therapies such as Klotho Protein Supplementation to Extend Healthy Human Lifespan September 9, 2024 | 6 min read Twitter LinkedIn Facebook Email Print MIAMI, Sept. 09, 2024 (GLOB … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s DiseaseILAP Designation accelerates patient access and commercialization - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Releas … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s DiseaseILAP Designation accelerates patient access and commercialization April 5, 2023 | 8 min read Twitter LinkedIn Facebook Email Print ADvantage Therapeutics, Inc. (“ADvantage” or “the … n other worldwide healthcare systems.” The Phase 2b trial for AD04™ in the ILAP application will be a randomized, placebo-controlled, double-blind study to confirm proof of concept and establish the safety and efficacy of AD04™ in mild AD patients. The 12-month study will measure hippocampal volume as an objective/biomarker endpoint. Other measured outcomes include the Alzheimer’s Disease Assessment scale – cognition 13-item scale (ADAScog13), the Alzheimer’s Disease Cooperat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic September 29, 2025 | 4 min read Twitter LinkedIn Facebook Email Print MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a biotechnology company developing novel the … been awarded a $2.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health (NIH). This non-dilutive grant will further important research supporting AD04 ® , the company’s phase 2 Alzheimer’s candidate. “This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH support, we are one step closer to helping patients suffering fr … approval after phase 2) and EU CTAs validates AD04 ® as a global program. This award positions us to accelerate regulatory momentum and attract the strategic partners required for broad patient access,” said Jeffrey Madden, Co-Founder and CEO. This news follows the recent publication of encouraging AD04 ® results in The Journal of Prevention of Alzheimer’s Disease (JPAD) https://pubmed.ncbi.nlm.nih.gov/40953123/ . The publication highlighted encouraging results from A … he National Institute on Aging (NIA) of the National Institutes of Health under Award Number 1R44AG091827-01. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. For more information, please visit: www.advantagetherapeutics.com Media Contact: Jeffrey Madden Chief
Klogenix宣布知识产权组合被ADvantage Therapeutics公司收购-动脉网 APP 扫码下载 产业链接 公众号矩阵 动脉网 动脉新医药 动脉橙果局 产业链接 VBEF发布 动脉生物制造 透皮技术创新联盟TTIA 动脉智库 活动会议 2025数字疗法大会 CSGCT第二届中国细胞与基因治疗大会 2026未来医疗100强大会 2025VBEF直播回放&百强榜单 全部活动 解决方案 动脉AI 搜索 EN 登录 首页 情报 原创 专题 报告 链接 直播 活动 动脉网APP 扫码下载 Klogenix宣布知识产权组合被ADvantage Therapeutics公司收购 Klogenix’ pioneering research on age-related diseases and longevity gene Klotho finds new home at ADvantage Therapeutics, Inc. GlobeNewswire 等信源发布 2023-10-02 23:12 可切换为仅中文 微信扫码分享 BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Klogenix LLC (“Klogenix” or “the Company”) is pleased to
#podcast Jeffrey Madden,... - Digital Politics Podcast Facebook Log In Digital Politics Podcast's Post Digital Politics Podcast December 18, 2023 · Shared with Public #podcast Jeffrey Madden, Co-Founder and CEO of ADvantage Therapeutics is developing therapies for neurodegenerative conditions, particularly Alzheimer's disease. Instead of pursuing the amyloid hypothesis, ADvantage is focused on neuroinflammation as the primary driver of Alzheimer's pathology. Trials for their lead compound AD04 show promising results in slowing hippocampal volume loss and stabilizing cognition. J
Empowered Patient Podcast: Lead Compound Targets Neuroinflammation Slowing Alzheimer’s Progression with Jeffrey Madden ADvantage Therapeutics TRANSCRIPT | Karen Jagoda LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree
#podcast Jeffrey Madden,... - Empowered Patient Radio Facebook Log In Empowered Patient Radio's Post Empowered Patient Radio December 18, 2023 · Shared with Public #podcast Jeffrey Madden, Co-Founder and CEO of ADvantage Therapeutics is developing therapies for neurodegenerative conditions, particularly Alzheimer's disease. Instead of pursuing the amyloid hypothesis, ADvantage is focused on neuroinflammation as the primary driver of Alzheimer's pathology. Trials for their lead compound AD04 show promising results in slowing hippocampal volume loss and stabilizing cognition. Jeff
Empowered Patient Podcast Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing Healthcare Protesting Healthcare workers Hospitals Hypertension Immunotherapies Infectious diseases Maker Movement Marijuana Medtech Mental Health Min … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
Empowered Patient Podcast: Lead Compound Targets Neuroinflammation Slowing Alzheimer’s Progression with Jeffrey Madden ADvantage Therapeutics TRANSCRIPT Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing Healthcare Protesting H … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories | Yuki Sakakibara LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue t … age Therapeutics Inc. is making a different bet. With a $2.5M NIH Phase II SBIR grant, the company is advancing AD04—a subcutaneous immunomodulatory candidate that aims to deliver functional slowing without the infusion burden or ARIA monitoring. This isn’t just a scientific play; it’s a deliberate operational and regulatory positioning. AD04 already has UK ILAP designation and European CTAs in place, setting up a confirmatory Phase 2b trial designed for hybrid administration … ACP, FACG, AGAF 8mo Report this post Continuing on the topic of T reg and Nobel Prize From our colleagues from Europe: 🧬 In vitro-expanded 'thymus-derived' regulatory T cells (tTreg) have shown promise in preclinical models of IBD, leading to interest in their use as a potential therapy in CD. Earlier this year they published a study protocol for a first-in-human study of Tregs for IBD using ex vivo Treg expansion. This study will explore the preliminary safety and tolerabil
Getting a drug across the blood–brain barrier (BBB) remains one of the biggest challenges for treating neurodegenerative diseases. The BBB is a marvel of nature - an essential first line of defense… | Netrang Desai LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at … e betting that treatments developed for rare mitochondrial mutations could also apply to these broader, more prevalent diseases. ✨ This first approval isn’t just a win for patients — it’s a signal that mitochondrial medicine is moving from promise to proof. https://lnkd.in/dgvF9QRw First approved drug for mitochondrial disease could pave way for more treatments science.org 43 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Mass General … age Therapeutics Inc. is making a different bet. With a $2.5M NIH Phase II SBIR grant, the company is advancing AD04—a subcutaneous immunomodulatory candidate that aims to deliver functional slowing without the infusion burden or ARIA monitoring. This isn’t just a scientific play; it’s a deliberate operational and regulatory positioning. AD04 already has UK ILAP designation and European CTAs in place, setting up a confirmatory Phase 2b trial designed for hybrid administration
Madden Center for Value Creation: Entrepreneurship & Longevity Conference | FAU Business FLORIDA ATLANTIC UNIVERSITY ® COLLEGE OF BUSINESS QUICK LINKS Alumni Business Communications Economics Executive Education Faculty in the Media Faculty Research Finance Giving Health Administration Hospitality & Tourism Management Information Technology & Operations Management Management Programs Marketing Masters & Ph.D. School of Accounting open menu close menu College of Business Home Page Our Research Centers & Trading Room Madden Center for Value Creation Madden Cente … r Sramek , CEO, Healthy Longevity Clinic, Managing Partner at VC Longevity Tech Fund Dr. Rudy Tanzi, Professor of Neurology, Harvard Medical School, Director of the Genetics and Aging Research Unit, MGH Dr. Siri Terjesen , Phil Smith Professor, Associate Dean of Research & External Relations, Executive Director, Madden Center for Value Creation at Florida Atlantic University Andre Watson , Chairman and CEO, Ligandal Speaker roster is subject to change. For registration in … er Partner - Iron Bridge Capital Management Jim O'Neill , Co-founder, the Thiel Fellowship, Former HHS Official James Peyer , CEO, Cambrian Bio Walter Schmidt , Director, mRNA Division, ADvantage Therapeutics Richard Serbin , Former Global Head of Corporate Development for Johnson & Johnson, Regulation and Patent Attorney, Pharmacist Alfred Slanetz , President & CEO, Geneius Biotechnology, Inc. Siri Terjesen , Phil Smith Professor, Associate Dean of Research & Ext … es 30Under30 Healthcare 2021 E-NEWS SIGN-UP sign up Apply Now ---> Privacy Policy REGULATIONS & POLICIES CONSUMER INFORMATION Employment Opportunities Get Help Accessibility Contact us Florida Atlantic University 777 Glades Road Boca Raton, FL 33431 Campuses: Boca Raton Dania Beach Davie Fort Lauderdale Harbor Branch Jupiter FAU Business facebook instagram linkedin twitter youtube FAU Executive Education facebook instagram linkedi
ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bus … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease November 27, 2023 | 6 min read Twitter LinkedIn Facebook Email Print ADvantage Therapeutics, Inc. today announced the first patient enrolled in the Company’s E … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia June 20, 2023 | 6 min read Twitter LinkedIn Facebook Email Print ADvantage Therapeutics, Inc. today announced that regulatory authorities in Poland, … authorities in Poland, Bulgaria, and Slovakia have approved its Clinical Trial Application (CTA) to conduct a clinical trial on its lead candidate, AD04™ for the treatment of mild Alzheimer’s disease (AD) in each respective country. MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions with a focus on Alzheimer’s disease, today announced that regulatory authorit … authorities in Poland, Bulgaria, and Slovakia have approved its Clinical Trial Application (CTA) to conduct a clinical trial on its lead candidate, AD04™ for the treatment of mild Alzheimer’s disease (AD) in each respective country. The Phase 2b study authorized in these countries will be a randomized, double-blind, placebo-controlled trial aimed at confirming proof-of-concept and establishing the safety and efficacy of AD04™ in patients with mild AD. The 12-month stud … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ADvantage Therapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & … 21.24M over 5 rounds . ADvantage Therapeutics's latest funding round was a Grant for $2.5M on September 26, 2025 . Date Round Amount Investors Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. Revenue Sources 9/26/2025 Grant $2.5M National Institute on Aging $XXM 0 FY undefined 2 7/28/2025 Seed VC - II Subscribe to see more $XXM 0 FY undefined 10 7/12/2023 Seed VC $XXM … 0 FY undefined 10 Date 9/26/2025 7/28/2025 7/12/2023 6/15/2022 6/25/2021 Round Grant Seed VC - II Seed VC Option/Warrant Seed Amount $2.5M $XXM $XXM $XXM Investors National Institute on Aging Subscribe to see more Subscribe to see more Subscribe to see more Subscribe to see more Valuation $XXM $XXM $XXM $XXM $XXM Revenue 0 FY undefined 0 FY undefined 0 FY undefined 0 FY undefined 0 FY undefined Sources 2 10 10 10 10 Learn more by requesting a demo ADvantage Therapeutics Inve … vestors . National Institute on Aging invested in ADvantage Therapeutics's Grant funding round . First funding Last Funding Investor Rounds Board Seats Type Location 9/26/2025 9/26/2025 National Institute on Aging 1 Grant Government Maryland 00/00/0000 00/00/0000 quadraScope Ventures Subscribe to see more Venture Capital Massachusetts 00/00/0000 00/00/0000 EQT Life Sciences Subscribe to see more Venture Capital Netherlands First funding 9/26/2025 00/00/0000 00/00/0000 La … tor National Institute on Aging quadraScope Ventures EQT Life Sciences Rounds 1 Grant Subscribe to see more Subscribe to see more Board Seats Type Government Venture Capital Venture Capital Location Maryland Massachusetts Netherlands Learn more by requesting a demo Loading... 498 Seventh Avenue 12th floor New York, NY 10018 [email protected] 21
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
SENS Research Foundation - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 SENS Research Foundation Private Company | California, United States | www.sens.org Private Company | California, United States | www.sens.org Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with SENS Research Foundation Login to view more data 0 Patents (Medical) associated with SENS Research Foundation Login to v … Fiona Miller, Managing Partner, QuadraScope, Jim O'Neill, Co-founder, the Thiel Fellowship, Former HHS Official, Dr. Achim Schneeberger, Chief Medical Officer, ADvantage Therapeutics, Yuri Deigin, Co-Founder, YouthBio Therapeutics, Petr Sramek, CEO, healthylongevity.clinic, Managing Partner, Longevitytech.fund, Dr. Jean Hebert, Professor, Albert Einstein College of Medicine, Daniel Gropper, Dean, FAU College of Business, Dr. Siri Terjesen, Phil Smith Professor, Associate Dean … nformal mentor to her, and they reconnected later when he interviewed her for a fellowship program. At the age of 17, Deming says de Grey sent her an inappropriate email from his work address, in which he detailed his “adventurous love life,” and admitted he had considered letting their conversations “stray in that direction.” “I was 17, and I assumed that I had done something terribly wrong” by entering the field at such a young age, Deming said in an interview. In her post, … e lifespan of dogs, while Deming is a venture capitalist who runs the Longevity Fund. Halioua had previously served as Deming’s chief of staff. De Grey co-founded SENS — which stands for “strategies for engineered negligible senescence” — in March 2009 with the notion that one can slow or control the aging process by addressing key diseases and repairing the damage that builds up in our bodies over time. The foundation’s recent fundraiser was aimed at boosting research capabi … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Klogenix’ pioneering research on age-related diseases and longevity gene Klotho finds new home at ADvantage Therapeutics, Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Klogenix’ pioneering research on age-related diseases and longevity gene Klotho finds new home at ADvantage Therapeutics, Inc. October 2, 2023 | 4 min read Twitter LinkedIn Facebook Email Print Klogenix LLC is pleased to announce that its intellectual property portfolio has been acquired by ADva … izations such as the NIH, Alzheimer’s Association, Boston University’s Ignition Award, the Massachusetts Neuroscience Consortium Award, the Cure AD Fund, and Alzheimer’s Drug Discovery Foundation. About Klogenix LLC. Klogenix is a Boston based pre-clinical stage biotech company targeting prevention and treatment of age-related diseases and extension of healthy lifespans. The company has been focused on the Klotho resilience and longevity gene since its inception. Klogenix pio … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide e … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ADvantage Therapeutics Secures $2.5M NIH Grant to Advance Alzheimer’s Candidate AD04® 26 June, 2026 | Friday Home Editorial 2026 Media Pack BioPharma Exclusive Subscribe Events Login BioPharma USFDA Drug Development Pharma Research Regulatory Clinical Trial Pharma Manufacturing Product Development and Pipeline Genomic and Personalized Medicine LifeSciences Biotech Biologics Clinical & Diagnostic Rare Diseases Therapeutics Lab Lab Products Lab Testing Contract Pharma Contract Research Contract Manufacturing Healthcare Digital Health Bio Innovation Public Health Cancer Technology Artifical I … Thailand Vietnam Regions North America ADvantage Therapeutics Secures $2.5M NIH Grant to Advance Alzheimer’s Candidate AD04® ADvantage Therapeutics Secures $2.5M NIH Grant to Advance Alzheimer’s Candidate AD04® 30 September 2025 | Tuesday | News The highly competitive SBIR Phase II award from the National Institute on Aging validates AD04®’s promise as a safer, more accessible Alzheimer’s therapy and strengthens the company’s regulatory and global development momentum. ADvant … been awarded a $2.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health (NIH). This non-dilutive grant will further important research supporting AD04 ® , the company’s phase 2 Alzheimer’s candidate. “This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH support, we are one step … roval after phase 2) and EU CTAs validates AD04 ® as a global program. This award positions us to accelerate regulatory momentum and attract the strategic partners required for broad patient access,” said Jeffrey Madden, Co-Founder and CEO. This news follows the recent publication of encouraging AD04 ® results in The Journal of Prevention of Alzheimer’s Disease (JPAD) https://pubmed.ncbi. nlm.nih.gov/40953123/ . The publication highlighted encouragi … S Research Workflows 03 June, 2026 Editor Picks Acurex Biosciences Awarded ASAP Grant to Advance Novel Parkinson’s Disease Therapeutic Research 28 May, 2026 H. Lundbeck A/S Secures South Korea Approval for Eptinezumab to Prevent Migraine in Adults 27 May, 2026 Cornerstone Robotics Wins EU CE Mark for Sentire® Surgical System, Expanding Into Europ
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Advantage Therapeutics spins out mRNA tech with initial focus on metabolic disease | Jeffrey Madden | 13 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … ied to aging. A heartfelt thank you to Petr Sramek and the entire Longevitytech.fund team for believing in our vision, to Dr. Carmela Abraham for her groundbreaking research on Klotho, and to the entire ADvantage Therapeutics team, whose dedication and expertise have made this milestone possible. Together, we are advancing the boundaries of what's possible in healthy aging and lifespan extension. Here's to a future where longer, healthier lives become a reality for all. Let’s
ADvantage Therapeutics Announces Breakthrough Findings in Alzheimer's Disease Treatment: AD04TM shows immediate symptomatic and disease-modifying properties - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Dev … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases ADvantage Therapeutics Announces Breakthrough Findings in Alzheimer’s Disease Treatment: AD04TM shows immediate symptomatic and disease-modifying properties July 31, 2024 | 5 min read Twitter LinkedIn Facebook Email Print PHILADELPHIA, July 30, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics today announc … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NIBA September 6-7, 2023 Ft. Lauderdale, FL Conference – NIBA – National Investment Banking Association – OFFICIAL SITE Home About NIBA NIBA Board of Directors and Committees NIBA Internship Contact NIBA Sign up for updates! Close Conferences NIBA October 6-7, 2026 Ft. Lauderdale, FL Conference NIBA March 11-12, 2026 Ft. Lauderdale, FL Conference NIBA September 16-17, 2025 Ft. Lauderdale, FL Conference NIBA September 4-5, 2024 Ft. Lauderdale, FL Conference NIBA September 6-7, 2023 Ft. Lauderdale, FL Conference NIBA September 7-8, 2022 Hollywood, Florida Conference NIBA Novemb
Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics - Advantage Therapeutics | ADvantage Therapeutics Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time
--> Donate | website top of page 1 Horse At A Time Draft Horse Rescue Corvallis/Montana ... where new life begins! PLEASE DONATE TODAY [email protected] | (406) 493-4978 Home Adoption Application Our Horses Meet our horses Our sanctuary horses Rainbow Pastures Volunteer Donate Sponsorship Training Sponsorship Program Rose's … Volunteer Donate Sponsorship Training Sponsorship Program Rose's Memorial Fund Events Happy Adoptions Financials/Reports Shop About us / Board Members Educational References Blog More Use tab to navigate through the menu items. YOUR DONATION WILL MAKE A DIFFERENCE! 1 Horse At A Time Draft Horse Rescue is a 501(c)3 organization fully funded by the public. We rely on generous donations from our community members and individuals who follow our efforts via social media si … bscribe to our Newsletter! And be the first to receive important notifications! Submit [email protected] ph (406)493-4978 ©2017 by 1 Horse At A Time Draft Horse Rescue. Proudly created with Wix.com bottom of page
Agustin Fernandez Santana III – Klotho Conference Skip to main content Skip to footer Register Agenda Speakers Klotho Conference & Scientific Seminar Sponsorships About Contact Agenda Register Speakers Sponsorships About Contact the klotho conference Agustin Fernandez Santana III Founder and CEO of Klothea Bio, Rational Vaccines, Founder and Chairman of ADvantage Therapeutics. Prior to his biotech career Mr. Fernandez served as the managing director of Mega films, the production arm of the Spanish Broadcasting System (SBSA), and CEO of Duende Media, Inc. where he structured over $100M of … red over $100M of film and television financing. Mr. Fernandez is a 9-time EMMY award winning writer/director/producer and the executive producer of the 2014 academy award winning documentary “The Lady In Number Six”. Events Join us on September 17-18, 2026 The second annual Klotho conference will bring together virtually leading scientists, drug developers, clinicians, thought leaders, analysts and investors to foster vibrant discussions and debate on the future of Klotho-ba
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account October 09, 2025 06:52 ET | Source: ADvantage Therapeutics, Inc. Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio September 26, 2025 08:43 ET | Source: ADvantage Therapeutics, Inc. UPDATE -- ADvantage The … erapeutics, Inc. UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic September 26, 2025 06:52 ET | Source: ADvantage Therapeutics, Inc. ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic ADvantage The … D04® Toward the Clinic ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic May 15, 2025 10:04 ET | Source: ADvantage Therapeutics, Inc. Klothea Bio Collaborates with Healthy Longevity Clinic, a Top 40 Semifinalist in $101 million XPRIZE Healthspan Competition MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Klothea Bio Inc., a biotechnology company pioneering mRNA-based therapies to upregulate the anti-aging prot
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Jim O’Neill Confirmed as HHS Deputy Secretary Home Acquisition & Procurement Agencies DoD Intelligence DHS Civilian Space Cybersecurity Technology Awards News About Wash100 Contact Us Advertising Submit your news No Result View All Result Home Acquisition & Procurement Agencies DoD Intelligence DHS Civilian Space Cybersecurity Technology Awards News About Wash100 Contact Us Advertising Submit your news No Result View All Result No Result View All Result Home Executive Moves Jim O’Neill Confirmed as HHS Deputy Secretary by Jane Edwards June 9, 2025 in Executive Moves , News The Senate v … s. The Senate on Thursday confirmed Jim O’Neill , co-founder of the Thiel Fellowship, as deputy secretary of the Department of Health and Human Services in a 52-43 vote. Table of Contents Toggle You might also like White House Submits $87.6B Supplemental Funding Request to Congress CISA Issues Zero Trust Guide Supporting TIC 3.0 Adoption DOW Updates CBRN Survivability Requirements Jim O’Neill’s Career Background You might also like White House Submits $87.6B … Jim O’Neill’s Career Background O’Neill co-founded the Thiel Fellowship in 2010 and served as CEO of SENS Research Foundation. According to his LinkedIn profile, he sits on the board of Advantage Therapeutics and is an adviser at FounderPool. The Yale University graduate was managing director at Mithril Capital Management and Clarium Capital Management. O’Neill also held leadership roles at HHS during President George W. Bush’s administration, i … Space Cybersecurity Technology Awards News About Wash100 Contact Us Advertising Submit your news Copyright 2026 Executive Mosaic . All Rights Reserved. Get your free GovCon news! Get your latest GovCon news and insights. Become a VIP and subscribe to the GovConWire Daily News. Invalid email address We promise not to spam you. You can unsubscribe at any time. Thanks for subscribing!
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
ADvantage Therapeutics Announces Breakthrough Findings in --> Accessibility: Skip TopNav ADvantage Therapeutics Announces Breakthrough Findings in Alzheimer's Disease Treatment: AD04TM shows immediate symptomatic and disease-modifying properties July 30, 2024 12:04 ET | Source: ADvantage Therapeutics, Inc. ADvantage Therapeutics, Inc. PHILADELPHIA, July 30, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics today announced groundbreaking results from a study on AD04™, a novel therapeutic candidate for Alzheimer's disease. Scientists from ADvantage presented the research poster "AD04™ - mod
ADvantage Therapeutics Announces Breakthrough Findings in Alzheimer's Disease Treatment: AD04TM shows immediate symptomatic and disease-modifying properties | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
ProMIS CEO talks Alzheimer's disease and PMN310 | Precision AQ - Investor Relations & External Communications posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By … ective was to design and initiate that 1B Alzheimer's study. So complete the 1A fund the company initiate the 1B. That was the goal for last year and the team succeeded tremendously. It was some pretty heavy lifting there, but we did very well in the financing was an important milestone to secure funding for the for the 1B study. And I think that importantly, and I'll touch on the 2025 in a second, and I think one of the important elements of the, of the financing and the, an … ticals Inc. → expanding brain disorder programs. 💊 $2.6M – AlzeCure Pharma (EU Grant) → supporting Phase 2 clinical development. 🧪 $2.5M – ADvantage Therapeutics Inc. (NIH SBIR) → advancing AD04®, an immunomodulatory Alzheimer’s drug. 🔬 $1.5M – C2N Diagnostics → refining biomarker assays for earlier detection. 🧬 $250K – Circular Genomics → fueling early discovery platforms. 📊 Funding activity often reflects where momentum is building, and for commercial teams, it’s a dir
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
ADvantage Therapeutics Toggle Navigation Apply Contact Research Back Research at Vienna BioCenter Research Entities Research Areas Research Areas Open Submenu Back Back to Research Areas Anthropogenic Evolution Biochemistry, Biophysics, Structure Cell and Chromosome Biology Cognitive and Behavioral Biology Computational Biology, Genomes and Evolution Disease Mechanisms, Immunology, Pathogens Gene Regulation, RNA, Epigenetics Microbiology and Environmental Systems Science Neurobiology Plant Sciences Stem Cells, Development, Regeneration Research Groups Key Discoveries Key Discoveries Open Subme
Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics - Advantage Therapeutics About Us Our Science Pipeline Our Team News News Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics November 26, 2024 November 26, 2024 Klothea Bio Secures Funding from Longevitytech.fund as a lead investor to Pioneer BreakthroughTreatments for Metabolic Syndrome and several Aging-Associated Diseases MIAMI, Nov. 2 … ed conditions. The new subsidiary is backed by seed funding ledby Longevitytech.fund (“LTF”), a prominent venture capital fund managed by Petr Sramek that invests inbiotechnology startups focused on healthy lifespan extension globally. Klothea Bio, Inc. will build upon Advantage Therapeutics’ proprietary IP portfolio centered around Klotho, a protein renowned for its significant anti-aging properties, including neuroprotection, antioxidativeeffects, and tumor suppression. Klo … titude for the investment andhighlighted the strategic focus that Longevitytech.fund will bring to the company’s anti-aging research. “We arethrilled to partner with Longevitytech.fund as our lead investor, advancing our mission to realize thetransformative potential of Klotho protein therapies for aging-related diseases. This collaboration strengthensKlothea Bio’s laser focus on developing safe and effective treatments as we prepare for our upcoming clinicaltrial, brin … n lifespan is achievable.” Petr Sramek, Managing Partner of Longevitytech.fund and Klothea Board Member, expressedenthusiasm for supporting Klothea Bio’s mission. “Longevitytech.fund is committed to advancing solutions thataddress the hallmarks of aging, and we see Klotho as a critical protein in a molecular pathway to enhancehuman health and longevity. By supporting Klothea Bio, we aim to enable pioneering science that holds thepromise of reducing the burden of a … y conducts early preclinical research and drug development. About Longevitytech.fund Longevitytech.fund (“LTF”) is a venture capital fund focused on pre-seed and seed-stage investmentsin early-stage biotech startups and university spinoffs worldwide. Through close cooperation with topscientists in aging research, biotechnology, bioinformatics, ag
ADvantage Therapeutics Welcomes Esteemed Expert in Alzheimer’s Disease and Klotho Protein, Carmela Abraham, Ph.D. as Chief Science Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactur … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business ADvantage Therapeutics Welcomes Esteemed Expert in Alzheimer’s Disease and Klotho Protein, Carmela Abraham, Ph.D. as Chief Science Officer October 2, 2023 | 6 min read Twitter LinkedIn Facebook Email Print In a transformative move bolstering its position in the realm of neurodegenerative ther … ions such as the NIH, the Alzheimer’s Association, Boston University’s Ignition Award, the Massachusetts Neuroscience Consortium Award, the Cure AD Fund, and Alzheimer’s Drug Discovery Foundation. “Through ADvantage Therapeutics’s pioneering compound AD04, and our exploration of the klotho protein's applications, we are at the forefront of redefining approaches to combat Alzheimer’s disease and the aging process,” said Dr. Abraham. “Having dedicated my career to these goals, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board --> Accessibility: Skip TopNav Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio World-renowned longevity physician to help guide Klothea Bio as it prepares for a Phase 1B clinical trial of its Klotho therapeutic for aging related diseases October 09, 2025 06:52 ET | Source: ADvantage Therapeutics, Inc. ADvantage Therapeutics, Inc. MIAMI, Oct. 09, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or the “Company”), a clinical-stage biotec … icensing and Access Pathway (ILAP) . The Company also recently announced an NIH grant in support of IND enabling research on AD04™. About Advantage Therapeutics Inc. Advantage Therapeutics, Inc. is at the forefront of developing next-generation therapies aimed at modifying the course of Alzheimer’s disease and other age-related conditions. The company is committed to addressing the unmet medical needs of patients through cutting-edge science and innovative treatment approache
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Advantage Therapeutics Inc. Forms Klothea Bio, Inc. for Klotho Protein R&D in Age-Related Therapies Products Data Feature Plans Request Demo Sign Up for Free Advantage Therapeutics Inc. Forms Klothea Bio, Inc. for Klotho Protein R&D in Age-Related Therapies 3 December 2024 Advantage Therapeutics Inc. , a prominent developer of therapies for age-related diseases , has announced the launch of its new subsidiary, Klothea Bio, Inc. This new entity will concentrate on the research and development of Klotho -based therapies aimed at preventing and treating various age-related conditions. The … elated conditions. The initiative is backed by seed funding, with Longevitytech.fund (LTF) as the lead investor. LTF is a venture capital fund managed by Petr Sramek, focusing on biotechnology startups that aim to extend healthy lifespans globally. Klothea Bio will leverage Advantage Therapeutics' proprietary intellectual property portfolio that revolves around Klotho, a protein known for its substantial anti-aging properties. These properties include neuroprotection, antioxi … n also emphasized the strategic importance of the investment from Longevitytech.fund, which he believes will advance Klothea Bio’s mission to harness the transformative potential of Klotho protein therapies for aging-related ailments. This collaboration is seen as a critical step towards developing safe and effective treatments, with upcoming clinical trials in the pipeline. Petr Sramek, Managing Partner of Longevitytech.fund and a member of Klothea Bio’s board, shared his ex … excitement about supporting the company’s mission. He highlighted Longevitytech.fund's commitment to finding solutions that address the hallmarks of aging. Sramek sees Klotho as a crucial protein in the molecular pathway that can enhance human health and longevity. By supporting Klothea Bio, Longevitytech.fund aims to promote pioneering science that could reduce the burden of age-related diseases. Dr. Carmela Abraham, Chief Science Officer at Advantage Therapeutics, has studi … metabolism, improve phagocytosis, and reduce inflammation. About Longevitytech.fund Longevitytech.fund is a venture capital fund focusing on early-stage biotech startups and university spinoffs worldwide. By collaborating with top scientists in aging research, biotechnology, bioinformatics, agetech, and AI, Longevitytech.fund provides active sup
%PDF-1.6 %���� 1667 0 obj > endobj 1699 0 obj >/Filter/FlateDecode/ID[ ]/Index[1667 105]/Info 1666 0 R/Length 154/Prev 3818984/Root 1668 0 R/Size 1772/Type/XRef/W[1 3 1]>>stream h�bbd```b`�V��, �� D2 ��i R�D���R R2L��Ie)�Hr�p�͑���E 6�Q�9- 2-Dr���`��s�6�`� ��̶�|� ���HA� ���� �˚) L� l�`�30�R��t��?�� b�� endstream endobj startxref 0 %%EOF 1771 0 obj >stream h��Y{lS��];�������� I�X�Z�mn��8�T/�h@Iq�#��� �&�aIzI1i�v�cZ�TAF�i���y���y �X5�QeL;�k�I`��@����9��� ��{u@Ho@PEС��#29�@���FH�0���������^�ҡ�� T�9$�����8����#W:�9���=7� ���My[G\������O�h �C����]�-wM�@ … 931e645efc7 xmp.did:8bcac1d1-52da-43aa-b1e6-ee0f35f02002 default converted from application/x-indesign to application/pdf Adobe InDesign CC 13.1 (Macintosh) / 2018-09-18T14:21:13+02:00 application/pdf aws_bob lisa_anzeigen_A5_.indd Adobe PDF Library 15.0 False PDF/X-1:2001 PDF/X-1:2001 PDF/X-1a:2001 endstream endobj 1694 0 obj >stream H��Wmo�F�^��a��Ҫ5 ؾ�$!�.$(��ݧh��`������������y��I[�|b��g^v���b��� �V�(Μ��P?�0�˟5*⫫t�} Q7� � �z�h#���-�e�~G�$F��#�# �6"�c��f m>ʇ�B���^ … �UʳG,h�-�f�T�0ĎI��U�t���ׇ�:�3��G��� � endstream endobj 1695 0 obj >stream application/pdf AWS_reinz_Lisa_Anzeige 2013-09-06T13:48:44+02:00 2013-09-06T13:48:44+02:00 2013-09-06T13:48:44+02:00 Adobe Illustrator CS6 (Macintosh) 232 256 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx … 7FXYq7
FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYqkvnP/AJQ/Xv8Atm3n/JiTFX//2Q== application/pdf Adobe PDF Library 8.0 False endstream endobj 1697 0 obj >stream uuid:048f9183-8b18-ff4a-945f-651820dee4b2 adobe:docid:indd:c583a1b0-8501-11e8-b588-bb962be64498 proof:pdf 2018-09-10T10:30:41+02:00 2018-09-10T10:30:41+02:00 2018-09-10T10:30:41+02:00 Adobe InDesign CS3 (5.0) JPEG 256 256 /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4AE … 7FXYq7
FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYqkvnP/AJQ/Xv8Atm3n/JiTFX//2Q== application/pdf Adobe PDF Library 8.0 False endstream endobj 1698 0 obj >stream hޔ��k�0���{lز�l(���cЮ!��p�F��F�K������i,۰�����>M$K!"��?B( �CP`@ �JJÍ�j�r�i0/@��x �����!�@� 9�P`�?�\�\@A �x��ɻM:>`��Px#��w|�I|'�1+�;ϧy��4�y�,���w� �NE�� sT��+�
ADvantage Therapeutics Inc. - HQ | The Org Platform Enrich Pricing Log in Sign up ADvantage Therapeutics Inc. Offices HQ Unverified HQ 2 people · 0 jobs ADvantage Therapeutics Inc.'s headquarters in Miami, FL, United States Office location People ( 2 ) Jeffrey Madden Co-founder And CEO JS Juliana Scaminaci Business Administration Manager Jobs ( 0 ) No jobs in this office Other offices View all offices No other offices Company About Contact Blog Business Solutions Trust Pricing Directory Companies People Features Employer Branding Professional Networking Job Discovery Social © 2026 Orgio
%PDF-1.4 %���� 51 0 obj > endobj xref 51 180 0000000016 00000 n 0000004539 00000 n 0000004602 00000 n 0000004977 00000 n 0000005655 00000 n 0000005964 00000 n 0000008620 00000 n 0000009914 00000 n 0000011741 00000 n 0000013765 00000 n 0000013801 00000 n 0000013913 00000 n 0000014441 00000 n 0000014550 00000 n 0000014986 00000 n 0000016106 00000 n 0000016963 00000 n 0000017762 00000 n 0000018600 00000 n 0000019564 00000 n 0000020570 00000 n 0000021409 00000 n 0000022352 00000 n 0000022545 00000 n 0000022668 00000 n 0000023020 00000 n 0000023255 00000 n 0000023406 00000 n 0000023631 00000 n 0000 … 9:23Z Chromium 2023-06-20T13:22:18-04:00 2023-06-20T13:22:18-04:00 Skia/PDF m79 application/pdf uuid:ea304637-2198-b444-941d-dd4d9de09ac2 uuid:24882e2b-bf61-264c-affc-5b444fcb50cf endstream endobj 50 0 obj > endobj xref 0 51 0000000000 65535 f 0000109510 00000 n 0000109779 00000 n 0000114007 00000 n 0000114149 00000 n 0000114355 00000 n 0000114542 00000 n 0000115330 00000 n 0000115524 00000 n 0000115675 00000 n 0000116747 00000 n 0000116905 00000 n 0000117693 00000 n 00001183
UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic September 29, 2025 | 4 min read Twitter LinkedIn Facebook Email Print MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a biotechnology company developin … been awarded a $2.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health (NIH). This non-dilutive grant will further important research supporting AD04 ® , the company’s phase 2 Alzheimer’s candidate. “This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH support, we are one step closer to helping patients suffering fr … approval after phase 2) and EU CTAs validates AD04 ® as a global program. This award positions us to accelerate regulatory momentum and attract the strategic partners required for broad patient access,” said Jeffrey Madden, Co-Founder and CEO. This news follows the recent publication of encouraging AD04 ® results in The Journal of Prevention of Alzheimer’s Disease (JPAD) https://pubmed.ncbi.nlm.nih.gov/40953123/ . The publication highlighted encouraging results from A … he National Institute on Aging (NIA) of the National Institutes of Health under Award Number 1R44AG091827-01. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. For more information, please visit: www.advantagetherapeutics.com Media Contact: Jeffrey Madden Chief
%PDF-1.6 %���� 41 0 obj > endobj 42 0 obj > endobj 45 0 obj > stream H���yTSw�oɞ����c [���5la� QIBH�ADED���2�mtFOE�.�c��}���0��8��8G�Ng��� ��9�w���߽����'����0 �֠�J��b� 2y�.-;!���K�Z� ���^�i�"L��0���-�� @8(��r�;q��7�L��y��&�Q��q�4�j���|�9�� �V��)g�B�0�i�W��8#�8wթ��8_�٥ʨQ����Q�j@�&�A)/��g�>'K���t�;\�� ӥ$պF�ZUn��� �(4T�%)뫔�0C&�����Z��i���8��bx��E���B �;�����P���ӓ̹�A� om?�W= �x������-�����[���0� ���}��y)7ta�����>j���T�7���@���tܛ�`q�2��ʀ��&���6�Z�L�Ą? �_ ��yxg)˔z���çL�U���*�u�Sk�Se�O4?�c����.�� ��R� ߁��-��2�5������ ��S�>ӣV����d�`r��n~��Y�&�
MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s DiseaseILAP Designation accelerates… | Jeffrey Madden LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any
%PDF-1.7 %���� 1 0 obj >/Metadata 2502 0 R/ViewerPreferences 2503 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��V�oG~G��a����YvgK��`HJ% �DiU����Me�k�V��;��w ��^��og����������f�z� �W�Lp!��JJf%0�=ϋΗ���t?^v�Rt$�k���B�-�۷E�S�a�ʺvv� ] �L���^��J���i.43Fp �7Iv2�:�0`�i �c*��9ô0 _ˢc��J��C�r\[r��G,p �y�dJ\�xh-41K�h���-�$2ɭ�����K� @i�EK��5��ZH ����$�{������B�{bO�{3��ɴg�[�;���8 d�A��2�q�K����TNŶ�d|��>��Ǣ�{y��z|Y=��/�X�
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
%PDF-1.7 4 0 obj (Identity) endobj 5 0 obj (Adobe) endobj 8 0 obj > stream x��} |T����{�f��� $6$� I�X �#��Ȃ! $@H �Z�Z+��Z��Z��.T-Rkm�`�U(Z�A+�PQ�VT {��9������ߧ��s����9gΜ�;��Ehd�Z:����� Q�(�[�S�+'��'�������3��.\s;�؆R�j�jZ����s"y�\��6{Dpԫ�І���,m� � & �����ҚU-�O� ��KW�]�gۀ|��(��P_S���T��@zn"����u�Onhj�����w)�D~�-�o]9a���2Q���͵5 ��[��ѡ?5�\ۢn������7շ�����9D�O�~�ʚ���ï�DS��M-ͫ��\Z�*d�������Co# ���0�D�Us��uaX���A@n������?>s�m�����? o)d8����3�(�s�o �|���2 T�7��q��%*/!�ߒ����oW�u�R��oQ����4���5�n���xt�[�9"���&PzT�i)�]���it?�żEU�uFҒL����q^� ,#-5ep�cPRb\T�-,4$(0���g�TEP�
Company News - Page 2 of 3 - Advantage Therapeutics - Press Releases About Us Our Science Pipeline Our Team News COMPANY NEWS “Time Saved” Calculations to Improve Decision-Making in Progressive Disease Studies Published on April 9, 2024 April 9, 2024 Read more Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics Published on February 5, 2024 Read more ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease Published on Decemb … ction arising out of or relating to these Terms. You and ADvantage Therapeutics submit to the personal jurisdiction of such courts for those purposes. Any claim either party has against the other under these Terms must be brought within one (1) year after the cause of action arises. 10. General. The Terms constitute the entire agreement between you and us, superseding any prior or contemporaneous communications and proposals (whether oral, written, or electronic) between you … conduct, and reporting of research funded under all Public Health Service (PHS) grant awards is not biased by any conflicting financial interests of an Investigator. In addition, the policy serves to protect the safety of animals and human research participants, the reputation of the recipient institution and of the Investigator who participates in PHS-funded research. These requirements work together to preserve the public’s trust that the research supported by the PHS is co … ote objectivity in Public Health Service (PHS) funded research. The regulations apply to all PHS (e.g., National Institutes of Health [NIH]) funded grants, cooperative agreements, and research contracts, with the exception of Phase 1 Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) applications and/or awards. The regulation places the responsibility for the identification and management of Investigators’ FCOI with ADVANTAGE, which oversee … rs, including those at Subrecipient Institutions and Vendors that are paid with grant funds, comply with these requirements. Herein states ADVANTAGE’S FCOI policy that implements the regulatory requirements provided in 42 CFR Part 50 Subpart F to identify, collect, review, determine, manage and report FCOIs to NIH. This policy is applicable to “I
Sponsorships – Klotho Conference Skip to main content Skip to footer Register Agenda Speakers Klotho Conference & Scientific Seminar Sponsorships About Contact Agenda Register Speakers Sponsorships About Contact the klotho conference Sponsorships Sponsorship Opportunities Unlock powerful sponsorship opportunities at our conference, where your brand can connect with industry leaders, innovators, and decision-makers. Showcase your products or services, build valuable relationships, and gain unparalleled exposure to a targeted audience passionate about Klotho. Platinum $25,000 Gold $15,000 … th you. Sponsorship Level Platinum Gold Silver Bronze Academia Service Provider Submit Our Sponsors ADvantage Therapeutics Klothea Bio Lionheart Health Sponsorship Inquiry The Second Annual Klotho Conference on the future of Klotho-based therapies. Event Details Register Agenda Speakers Involvement Sponsorships Present About Contact © 2026 Leonhardt Ventures LLC. All rights reserved. Website Design by FizzPop Media
ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease - Advantage Therapeutics About Us Our Science Pipeline Our Team News News ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease December 1, 2023 MIAMI, November 27, 2023 (GLOBE NEWSWIRE) – ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of aging, today announced the first patient enrolled in the … ction arising out of or relating to these Terms. You and ADvantage Therapeutics submit to the personal jurisdiction of such courts for those purposes. Any claim either party has against the other under these Terms must be brought within one (1) year after the cause of action arises. 10. General. The Terms constitute the entire agreement between you and us, superseding any prior or contemporaneous communications and proposals (whether oral, written, or electronic) between you … conduct, and reporting of research funded under all Public Health Service (PHS) grant awards is not biased by any conflicting financial interests of an Investigator. In addition, the policy serves to protect the safety of animals and human research participants, the reputation of the recipient institution and of the Investigator who participates in PHS-funded research. These requirements work together to preserve the public’s trust that the research supported by the PHS is co … ote objectivity in Public Health Service (PHS) funded research. The regulations apply to all PHS (e.g., National Institutes of Health [NIH]) funded grants, cooperative agreements, and research contracts, with the exception of Phase 1 Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) applications and/or awards. The regulation places the responsibility for the identification and management of Investigators’ FCOI with ADVANTAGE, which oversee … rs, including those at Subrecipient Institutions and Vendors that are paid with grant funds, comply with these requirements. Herein states ADVANTAGE’S FCOI policy that implements the regulatory requirements provided in 42 CFR Part 50 Subpart F to identify, collect, review, determine, manage and report FCOIs to NIH. This policy is applicable to “I
Breakthrough: NIH Funds Alzheimer’s Drug AD04 with $2.5M Moe Alsumidaie Chief Editor Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation. Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Cell and Gene Therapy Clinical AI Clinical Decision Support Clinical Operations Clinical Research Clinical Trial Design Clinical Tri … September 27, 2025 ADvantage Therapeutics secured a $2.5 million Phase II SBIR grant from the National Institute on Aging to advance AD04, a subcutaneous immunomodulatory candidate for mild Alzheimer’s disease. The award follows publication of an earlier Phase 2 study and an independent statistical reanalysis indicating consistent signals on cognitive and quality-of-life measures, alongside slower hippocampal volume loss. The company also holds a UK ILAP designation and has … omarker evidence. ILAP can compress UK timelines through coordinated advice and rolling work packages, but it does not lower the evidentiary bar. In a market dominated by monoclonal antibodies with ARIA monitoring and infrastructure constraints, a safe, clinic-light alternative would appeal to sites and payers—provided effect sizes are durable and clinically interpretable. Competition from other non-amyloid approaches and anti-inflammatory mechanisms is intensifying, and regu … selection and SAP transparency, will signal program maturity. The $2.5 million award supports momentum but will not cover an EU Phase 2b; partnership or additional capital will be required, along with CMC readiness for scale. The central risk is that prior findings emerged from a control-arm effect; prospective replication is essential. If the Phase 2b delivers, ADvantage could pursue a UK conditional pathway and reshape site participation by offering a non-infusion option t … 5/09/26/3157020/0/en/UPDATE-ADvantage-Therapeutics-Awarded-2-5-Million-NIH-SBIR-Grant-to-Advance-Alzheimer-s-Drug-Candidate-AD04-Toward-the-Clinic.html Jon Napitupulu + posts Bio Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and tren
Renowned Public Health Advisor Jim O’Neill Joins Board of --> Accessibility: Skip TopNav Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton March 24, 2023 08:45 ET | Source: Advantage Therapeutics Inc. Advantage Therapeutics Inc. BOCA RATON, Fla. and VIENNA, Austria, March 24, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions wi … chnology companies. While leading the Thiel Foundation, he co-founded the Thiel Fellowship. He also served as a managing director at Clarium/Thiel Macro, a global macro investment fund. As CEO and board member of SENS Research Foundation (SRF), Mr. O’Neill oversaw strategy and operations for a team of scientists who research, develop, and promote comprehensive regenerative medicine solutions for the diseases of aging. SRF supports research focused on a damage repair paradigm
Jim O’Neill Joins Board of Directors of ADvantage Therapeutics | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
ADvantage Therapeutics Inc. | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies ADvantage Therapeutics Inc. ADvantage Therapeutics is dedicated to developing novel therapeutics for neurodegenerative conditions, with a major focus on Alzheimer’s Disease (AD). The company is currently approved for Phase 2 clinical trials in Europe and has an ILAP Passport designation from MHRA in the UK, which may allow for early commercialization after phase 2. With a research team at the Vienna BioCenter, ADvantage aims to create paradigm-chang
Caplight You need to enable JavaScript to run this app.
%PDF-1.6 %���� 7 0 obj > endobj 90 0 obj >/Filter/FlateDecode/ID[ ]/Index[7 147]/Info 6 0 R/Length 300/Prev 941168/Root 8 0 R/Size 154/Type/XRef/W[1 3 1]>>stream h��O+�Q�ϽC�W/�?eR��b!Y(�B�|) �Plg!���zV,(��XP,fcA�v�,$��=�X� >stream h�b``d``�d``�� > endobj 9 0 obj >/Font >/ProcSet[/PDF/Text/ImageC]/XObject >>>/Rotate 0/Type/Page>> endobj 10 0 obj >stream h��Zmo�8�+�x���_��l_� �lѦ�\�6R� �pܢ��w���X{@�^�!��3Ù! #�8N�"NF5q�0g�S��MM$�nhW�X#�s�1��)a�k8a�I �(��DPA8�+* GI��D���+m��n(ޱ�;�� � �D(K� ",6f�H/:� �Ę$R�d8�0 �u��!�Ylc�� QJ�dN��$sF���t�� �v�%��� E�� >R[����s# … 024-08-01T12:05:14-04:00 macOS Version 12.7.5 (Build 21H1222) Quartz PDFContext application/pdf uuid:e727777a-50f5-4b48-9d80-03dd60fc8b28 uuid:9ec79a2c-1d5b-8c42-a7c9-6672cc6d7288 endstream endobj 2 0 obj >stream h�2U0P���w�/�+Q0���L)�����T��$�����w � endstream endobj 3 0 obj >stream h�Ḻ �0�_���`sw�V�t�A\Ċ�P��&CA� �_�����Q]�6�a16ya����� �f^R����-1V�W� �B�>�' ��N��}|�: .벂Q ��p�t"f %\����9vaI��d�~_�' endstream endobj 4 0 obj >/Filter/FlateDecode/ID[ ]/Info 6
Thomas Hoffmann, Ph.D. - Advantage Therapeutics About Us Our Science Pipeline Our Team News Thomas Hoffmann, Ph.D. Contact us | Privacy Policy | Terms of use © 2026 ADvantage Therapeutics | All Rights Reserved × CONTACT US ADvantage Therapeutics Inc. 195 NW 40th Street Miami, FL 33127 Email: [email protected] Your name Your email Subject Your message (optional) × Terms of Use | FCOI Disclosure These Terms of Use (“ Terms ”) govern your use of our website at www.advantagetherapeutics.com as well as any other online services that ADvantage Therapeutics Inc. (“ ADvantage Therapeu … ction arising out of or relating to these Terms. You and ADvantage Therapeutics submit to the personal jurisdiction of such courts for those purposes. Any claim either party has against the other under these Terms must be brought within one (1) year after the cause of action arises. 10. General. The Terms constitute the entire agreement between you and us, superseding any prior or contemporaneous communications and proposals (whether oral, written, or electronic) between you … conduct, and reporting of research funded under all Public Health Service (PHS) grant awards is not biased by any conflicting financial interests of an Investigator. In addition, the policy serves to protect the safety of animals and human research participants, the reputation of the recipient institution and of the Investigator who participates in PHS-funded research. These requirements work together to preserve the public’s trust that the research supported by the PHS is co … ote objectivity in Public Health Service (PHS) funded research. The regulations apply to all PHS (e.g., National Institutes of Health [NIH]) funded grants, cooperative agreements, and research contracts, with the exception of Phase 1 Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) applications and/or awards. The regulation places the responsibility for the identification and management of Investigators’ FCOI with ADVANTAGE, which oversee … rs, including those at Subrecipient Institutions and Vendors that are paid with grant funds, comply with these requirements. Herein states ADVANTAGE’S FCOI policy that implements the regulatory requirements provided in 42 CFR Part 50 Subpart F to identify, collect, review, determine, manage and report FCOIs to NIH. This policy is applicable to “I
juliana scaminaci, Author at Advantage Therapeutics About Us Our Science Pipeline Our Team News Author: juliana scaminaci News Klothea Bio Announces the Launch of a Phase 1b Clinical Trial of AKL003, an Alpha Klotho mRNA Therapeutic, for the Extension of Human Lifespan February 23, 2026 MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) — Klothea Bio, Inc. (“Klothea Bio”), a clinical-stage biotechnology company developing therapeutics based on their proprietary serum klotho platform, today announced the launch of a randomized, double-blind, placebo-controlled Phase 1b clinical study evaluating AKL003 … icensing and Access Pathway (ILAP) . The Company also recently announced an NIH grant in support of IND enabling research on AD04™. About Advantage Therapeutics Inc. Advantage Therapeutics, Inc. is at the forefront of developing next-generation therapies aimed at modifying the course of Alzheimer’s disease and other age-related conditions. The company is committed to addressing the unmet medical needs of patients through cutting-edge science and innovative treatment approache … email protected] News ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic September 26, 2025 MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) — “This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH support, we are one step closer to helping patients suffering from this devastating condition.” The SBIR program is one of the most compet … approval after phase 2) and EU CTAs validates AD04 ® as a global program. This award positions us to accelerate regulatory momentum and attract the strategic partners required for broad patient access,” said Jeffrey Madden, Co-Founder and CEO. This news follows the recent publication of encouraging AD04 ® results in The Journal of Prevention of Alzheimer’s Disease (JPAD) https://pubmed.ncbi.nlm.nih.gov/40953123/ . The publication highlighted encouraging results from AD04’s e … he National Institute on Aging (NIA) of the National Institutes of Health under Award Number 1R44AG091827-01. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. For more information, please visit: www.advantagetherapeutics.com Media Contact: Jeffrey Madden Chief
ADvantage Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors &am … rapeutics.com Overview & Products Financials People Founded Year 2021 Stage Grant | Alive Total Raised $21.24M Last Raised $2.5M | 9 mos ago Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies. -83 points in the past 30 days About ADvantage Therapeutics ADvantage Therapeutics is a biotechnology company engaged in the development of therapies for neurodegenerative conditions, with a particular e … alzheimer's disease neurology ailments of unknown cause View Patents Chart Application Date Grant Date Title Related Topics Status 9/6/2019 11/5/2024 Increasing gene expression Clusters of differentiation, MicroRNA, Transcription factors, Molecular biology, Gene expression Grant Application Date 9/6/2019 Grant Date 11/5/2024 Title Increasing gene expression Related Topics Clusters of differentiation, MicroRNA, Transcription factors, Molecular biology, Gene expression Sta … ion, MicroRNA, Transcription factors, Molecular biology, Gene expression Status Grant Learn more by requesting a demo Latest ADvantage Therapeutics News Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio Oct 9, 2025 to further advance Klotho-Based Longevity Programs at Klothea Bio World-renowned longevity physician to help guide Klothea Bio as it prepares for a Phase 1B clinical trial of its Klotho ther … Licensing and Access Pathway (ILAP). The Company also recently announced an NIH grant in support of IND enabling research on AD04™. About Advantage Therapeutics Inc. Advantage Therapeutics, Inc. is at the forefront of developing next-generation therapies aimed at modifying the course of Alzheimer’s disease and other age-related conditions. The co
ADvantage Welcomes Dr. Mark Hyman to Advisory Board Sign In For User Subscribe Latest News Interview & Opinions Pharma Events For Leaders For Marketers AI in Pharma Magazine Pharma Manufacturing Research Papers HR in Pharma Knowledge Hub Guides Advertise with Us Podcasts Sign in Subscribe Sign in Latest News Interview & Opinions Pharma Events For Leaders AI in Pharma Magazine > latest-news ADvantage Therapeutics Welcomes Dr. Mark Hyman To Advisory Board To Advance Klothea Bio’s Klotho Longevity Initiatives ADvantage Therapeutics appoints Dr. Mark Hyman as Scientific and Medical Advi … Licensing and Access Pathway (ILAP). The company also recently announced an NIH grant supporting IND-enabling research for AD04™, further advancing its development pipeline. Ad Join Exclusive List Latest Home Latest News Interviews & Opinions Pharma Events Pharma Now Magazine Podcasts Untold Stories Learn Leadership Marketing Pharma Manufacturing AI in Pharma HR in Pharma Knowledge Hub Newsletter Archives Editors Choice Explore Advertise with Us List Your Company O … t Your Company Our Contributors Research Papers Advisory Team Contact Us Pharma Application Contribute Write for Us Submit your PR Join as Advisor Download App Follow Us Have any questions about Pharma Now? What is Pharma Now? Pharma Now is a leading monthly B2B magazine focused on delivering in-depth content related to the pharmaceutical and biopharma sectors. It covers the latest trends, technological innovations, leadership insights, market developments, and interviews wit … Yes, Pharma Now welcomes contributions from industry experts. Contributors can submit articles, thought leadership pieces, and case studies. You can register on the contributors' page to submit content and gain recognition for your insights. What advertising opportunities are available with Pharma Now? Pharma Now offers multiple advertising packages tailored to help companies promote their products, services, and innovations. From full-page ads to special event coverage
Jeffrey B. Madden - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Jeffrey B. Madden Chief Executive Officer at ADvantage Therapeutics, Inc. Jeffrey B. Madden 's Executive Work History Current Chief Executive Officer , Chief Executive Officer Equilar on 04/30/2026 ADvantage Therapeutics, Inc. Board Member , Board Mem
Jeffrey B. Madden - Advantage Therapeutics About Us Our Science Pipeline Our Team News Jeffrey B. Madden Contact us | Privacy Policy | Terms of use © 2026 ADvantage Therapeutics | All Rights Reserved × CONTACT US ADvantage Therapeutics Inc. 195 NW 40th Street Miami, FL 33127 Email: [email protected] Your name Your email Subject Your message (optional) × Terms of Use | FCOI Disclosure These Terms of Use (“ Terms ”) govern your use of our website at www.advantagetherapeutics.com as well as any other online services that ADvantage Therapeutics Inc. (“ ADvantage Therapeutics ,” “ … ction arising out of or relating to these Terms. You and ADvantage Therapeutics submit to the personal jurisdiction of such courts for those purposes. Any claim either party has against the other under these Terms must be brought within one (1) year after the cause of action arises. 10. General. The Terms constitute the entire agreement between you and us, superseding any prior or contemporaneous communications and proposals (whether oral, written, or electronic) between you … conduct, and reporting of research funded under all Public Health Service (PHS) grant awards is not biased by any conflicting financial interests of an Investigator. In addition, the policy serves to protect the safety of animals and human research participants, the reputation of the recipient institution and of the Investigator who participates in PHS-funded research. These requirements work together to preserve the public’s trust that the research supported by the PHS is co … ote objectivity in Public Health Service (PHS) funded research. The regulations apply to all PHS (e.g., National Institutes of Health [NIH]) funded grants, cooperative agreements, and research contracts, with the exception of Phase 1 Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) applications and/or awards. The regulation places the responsibility for the identification and management of Investigators’ FCOI with ADVANTAGE, which oversee … rs, including those at Subrecipient Institutions and Vendors that are paid with grant funds, comply with these requirements. Herein states ADVANTAGE’S FCOI policy that implements the regulatory requirements provided in 42 CFR Part 50 Subpart F to identify, collect, review, determine, manage and report FCOIs to NIH. This policy is applicable to “I
Frank Mattner - Präsident und CSO at ADvantage Therapeutics Inc. | The Org Platform Enrich Pricing Log in Sign up ADvantage Therapeutics Inc. Frank Mattner Unverified Frank Mattner Präsident und CSO Contact Frank Mattner began working at ADvantage Therapeutics Inc. in June 2021 as the President and CSO. Frank then transitioned to ADvantage Therapeutics GmbH in September 2021, while maintaining the same role. Frank Mattner attended Johannes Gutenberg University Mainz from 1984 to 1993, but no specific degree or field of study is indicated. Org chart View org chart 1 View manager View position
Frank Mattner - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Frank Mattner Board Member at ADvantage Therapeutics, Inc. Frank Mattner 's Executive Work History Current Board Member , Board Member Equilar on 07/28/2025 ADvantage Therapeutics, Inc. Past To view Frank Mattner's complete executive work history, sign up
ADvantage Therapeutics, Inc. - fund raising filing FormDs.com Newest Filter Local ADvantage Therapeutics, Inc. Industry: Other Health Care (See others in industry) Address: 195 Nw 40th Street Miami, FL, 33140 Phone: 630-886-7345 Filings Date Filing Type Reported Sold Incremental Cash Type Exemptions Link to Raw Filing 2025-07-28 Amended $13,737,491 $3,512,493 Equity Only 06b SEC link 2023-07-12 New $10,224,998 $10,224,998 Equity Only 06b SEC link 2022-06-15 New $275,000 $275,000 Other 06b SEC link 2021-06-24 New $5,000,000 $5,000,000 Equity Only 06b SEC link Directors and Executives (Current a
Agustin Fernandez Santana III - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Agustin Fernandez Santana III Executive Officer at ADvantage Therapeutics, Inc. Agustin Fernandez Santana III 's Executive Work History Current Executive Officer , Executive Officer Equilar on 07/28/2025 ADvantage Therapeutics, Inc. Board
%PDF-1.7 %���� 1 0 obj >/Metadata 109 0 R/ViewerPreferences 110 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 22 0 R 23 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]YoI�~o���o+Ft�U�`KvO����� f����m�Ԋ� �� WG��� ������r?=6G����|x��W ��g��>����& �%a �$����N�~�ϣ�%��HE-MK����� ]�e�����L�s2���o�[ؒ�;~+.誚�E��L�;�;`w���l�fT9�����be�ι����ck�'��݆K8a�b䁶��J�mh��Wq%��{ně%�߆%����oC�-^aɮ`ٞ���B�]�;� ��&��?i$�ys��,�~�� /��'e]�� ,p �k���UA��)� A�['_�m��m� … Tabs/S/Type/Page>> endobj 38 0 obj > endobj 40 0 obj > endobj 109 0 obj >stream application/pdf Jules Abraham Microsoft Word 2024-02-05T19:37:50Z 2024-02-05T14:48:05-05:00 2024-02-05T14:48:05-05:00 uuid:478BCDD9-8AA8-474A-82E9-F09B0B08E449 uuid:b0f7ce69-9642-c541-9174-61306ac12721 endstream endobj 112 0 obj > endobj 113 0 obj >stream H��W[o��~���X4w�����ɹ i Dm ���)Z�9�d�������gwG�҇}HL�{��7�7s��i������m�ٸ���s~����۬���ۛ��O�����܅�܅չ �s�s6�.l�]؝��?;����ܰ��Y���K��dv��'��
Company News - Advantage Therapeutics - Press Releases About Us Our Science Pipeline Our Team News COMPANY NEWS Klothea Bio Announces the Launch of a Phase 1b Clinical Trial of AKL003, an Alpha Klotho mRNA Therapeutic, for the Extension of Human Lifespan Published on February 23, 2026 Read more Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio Published on October 9, 2025 October 9, 2025 Read more ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic Pub … ction arising out of or relating to these Terms. You and ADvantage Therapeutics submit to the personal jurisdiction of such courts for those purposes. Any claim either party has against the other under these Terms must be brought within one (1) year after the cause of action arises. 10. General. The Terms constitute the entire agreement between you and us, superseding any prior or contemporaneous communications and proposals (whether oral, written, or electronic) between you … conduct, and reporting of research funded under all Public Health Service (PHS) grant awards is not biased by any conflicting financial interests of an Investigator. In addition, the policy serves to protect the safety of animals and human research participants, the reputation of the recipient institution and of the Investigator who participates in PHS-funded research. These requirements work together to preserve the public’s trust that the research supported by the PHS is co … ote objectivity in Public Health Service (PHS) funded research. The regulations apply to all PHS (e.g., National Institutes of Health [NIH]) funded grants, cooperative agreements, and research contracts, with the exception of Phase 1 Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) applications and/or awards. The regulation places the responsibility for the identification and management of Investigators’ FCOI with ADVANTAGE, which oversee … rs, including those at Subrecipient Institutions and Vendors that are paid with grant funds, comply with these requirements. Herein states ADVANTAGE’S FCOI policy that implements the regulatory requirements provided in 42 CFR Part 50 Subpart F to identify, collect, review, determine, manage and report FCOIs to NIH. This policy is applicable to “I
Advantage Therapeutics - A new Vantage on Alzheimer’s Disease About Us Our Science Pipeline Our Team News New Approaches for treating Alzheimer’s Disease ADvantage Therapeutics leverages novel mechanisms of action to address AD Mission: ADvantage Therapeutics is developing novel therapeutics to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently approved for Phase 2 clinical trials in Europe and possess an ILAP Passport designation from MHRA in the UK which may permit simultaneous clinical enrollment and early commercialization in the U.K after p … dly, the patients from the control group significantly benefited from the AD04™ application. Patients treated with AD04™ saw reduced hippocampal shrinkage—a region critical for memory and spatial orientation—and a corresponding slowdown in cognitive decline. In 2021, Frank Mattner, Walter Schmidt, Agustin Fernandez and Jeffrey Madden founded ADvantage Therapeutics Inc. to provide Alzheimer’s patients with a transformative, life-enhancing treatment. Summary of Phase 2: A … aging related diseases... ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- “This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH... Klothea Bio Collaborates with Healthy Longevity Clinic, a Top 40 Semifinalist in $101 million XPRIZE Healthspan Competition Advantage Therapeutics Inc. Announc … ein for Age-Related Therapeutics Klothea Bio Secures Funding from Longevitytech.fund as a lead investor to Pioneer BreakthroughTreatments for Metabolic Syndrome and several Aging-Associated Diseases MIAMI, Nov. 25, 2024... ADvantage Therapeutics Welcomes Dr. William Haseltine as Strategic Advisor to Drive Innovation AD04T™ – modifying Alzheimer’s disease by modulation of hippocampal lipid metabolism AAIC24_Poster_template v5 ADvantage Therapeutics Announces Break … Wells Fargo. More recently Mr. Buchsbaum helped manage the Holtzman Opportunity Fund, a shareholder activist hedge fund and private equity holdings for Jewelcor. He has a J.D. in Law from the University of Miami and a B.S. in business from the University of Richmond. × Olivier Jarry Chief Operating Officer “Alzheimer’s is one of the last fr